Company / R&D Expense
Idexx Laboratories R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$251.2M
FY2025
5-year range
$161.0M / $254.8M
FY2021-FY2025
Trend
+14.3%
vs FY2024
Sector context
#28 of 105
Health Care
What the data says
At $251M, Idexx Laboratories's r&d expense ranks #28 of 105 in the Health Care sector. Improved from $191M to $251M over the past 2 years.
Based on SEC 10-K filings.
$251M in FY2025 with a 5-year CAGR of +12.2%.
Improved from $191M to $251M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -0.5%
- 5-Year CAGR
- +12.2%
- 10-Year CAGR
- -
Sector benchmark
#28 of 105 in Health CareTop 27% of 105This company $251.2M Sector average $284.2M
▼
-11.6% below sector average
Key checks
Key Insights
- 5-year CAGR of +12.2%, indicating consistent growth.
- In FY2025, r&d expense increased 14.3% year-over-year.
- Ranks #28 out of 105 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2022.
Company context
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Altman Z-Score 4.60 (safe zone, above 2.9 threshold)
- Strong profit margin: 24.6%
- High earnings quality (cash-backed earnings)
- Strong return on equity: 65.8%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $251.2M | +14.3% |
| FY2024 | $219.8M | +15.1% |
| FY2023 | $191.0M | -25.1% |
| FY2022 | $254.8M | +58.3% |
| FY2021 | $161.0M | +14.0% |
| FY2020 | $141.2M | +6.0% |
| FY2019 | $133.2M | +13.0% |
| FY2018 | $117.9M | +8.0% |
| FY2017 | $109.2M | +8.0% |
| FY2016 | $101.1M | +1.4% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026